To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Synovial biomarkers and clincial scores of Orthovisc versus Hylan G-F20 in knee OA treatment

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
April 2019

Synovial biomarkers and clincial scores of Orthovisc versus Hylan G-F20 in knee OA treatment

Vol: 8| Issue: 4| Number:32| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis.

Ann Clin Lab Sci. 2004 Summer;34(3):330-5

Contributing Authors:
S Karatay A Kiziltunc K Yildirim RC Karanfil K Senel

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

40 patients with knee osteoarthritis were randomized to three weekly injections of either Orthovisc (Anika Therapeutics) or Hylan G-F20 (Synvisc; Genzyme). Primary outcomes were synovial fluid concentrations of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Clinical outcome on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue